Free Trial
NASDAQ:IMRX

Immuneering (IMRX) Stock Price, News & Analysis

Immuneering logo
$5.58 -0.02 (-0.36%)
As of 09:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Immuneering Stock (NASDAQ:IMRX)

Key Stats

Today's Range
$5.51
$5.72
50-Day Range
$2.44
$5.95
52-Week Range
$1.10
$6.18
Volume
20,029 shs
Average Volume
1.24 million shs
Market Capitalization
$202.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Moderate Buy

Company Overview

Immuneering Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

IMRX MarketRank™: 

Immuneering scored higher than 71% of companies evaluated by MarketBeat, and ranked 299th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Immuneering has only been the subject of 3 research reports in the past 90 days.

  • Read more about Immuneering's stock forecast and price target.
  • Earnings Growth

    Earnings for Immuneering are expected to grow in the coming year, from ($1.86) to ($1.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immuneering is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immuneering is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immuneering has a P/B Ratio of 7.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immuneering's valuation and earnings.
  • Percentage of Shares Shorted

    6.04% of the float of Immuneering has been sold short.
  • Short Interest Ratio / Days to Cover

    Immuneering has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immuneering has recently decreased by 5.45%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Immuneering does not currently pay a dividend.

  • Dividend Growth

    Immuneering does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.04% of the float of Immuneering has been sold short.
  • Short Interest Ratio / Days to Cover

    Immuneering has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immuneering has recently decreased by 5.45%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Immuneering has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Immuneering this week, compared to 2 articles on an average week.
  • Search Interest

    Only 4 people have searched for IMRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immuneering insiders have bought more of their company's stock than they have sold. Specifically, they have bought $334,318.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    22.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immuneering's insider trading history.
Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IMRX Stock News Headlines

Needham & Company LLC Reaffirms Buy Rating for Immuneering (NASDAQ:IMRX)
Immuneering Corporation: Ripping On A Questionable Catalyst
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
Immuneering Announces Closing of $25 Million Private Placement
See More Headlines

IMRX Stock Analysis - Frequently Asked Questions

Immuneering's stock was trading at $2.20 at the start of the year. Since then, IMRX shares have increased by 154.5% and is now trading at $5.60.

Immuneering Corporation (NASDAQ:IMRX) announced its earnings results on Wednesday, August, 13th. The company reported ($0.40) EPS for the quarter, meeting analysts' consensus estimates of ($0.40).

Immuneering (IMRX) raised $105 million in an IPO on Friday, July 30th 2021. The company issued 7,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Top institutional shareholders of Immuneering include Marshall Wace LLP (1.59%), Geode Capital Management LLC (0.64%), Bridgeway Capital Management LLC (0.27%) and Corient Private Wealth LLC (0.18%). Insiders that own company stock include Benjamin J Zeskind, Brett Matthew Hall, Peter Feinberg, Leah R Neufeld, Mallory Morales, Harold Eugene Brakewood and Diana Hausman.
View institutional ownership trends
.

Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immuneering investors own include Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD).

Company Calendar

Last Earnings
8/13/2025
Today
8/29/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMRX
CIK
1790340
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$8.00
Potential Upside/Downside
+132.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$61.04 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-146.28%
Return on Assets
-117.22%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.70
Quick Ratio
3.70

Sales & Book Value

Annual Sales
$320 thousand
Price / Sales
635.60
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.80 per share
Price / Book
7.00

Miscellaneous

Outstanding Shares
36,320,000
Free Float
28,002,000
Market Cap
$203.39 million
Optionable
Not Optionable
Beta
0.37

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:IMRX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners